S&P 500   5,095.59 (+0.17%)
DOW   39,171.53 (+0.26%)
QQQ   437.93 (-0.03%)
AAPL   182.71 (-0.90%)
MSFT   409.79 (-0.45%)
META   487.22 (+0.22%)
GOOGL   143.98 (-0.08%)
AMZN   174.82 (+0.14%)
TSLA   193.83 (-1.81%)
NVDA   798.15 (+1.63%)
NIO   5.46 (-6.67%)
AMD   175.54 (-3.48%)
BABA   76.30 (+0.24%)
T   16.80 (+1.27%)
F   12.20 (+0.66%)
MU   85.83 (-0.09%)
CGC   3.26 (-3.26%)
GE   153.48 (+1.19%)
DIS   107.11 (-0.49%)
AMC   4.47 (+1.13%)
PFE   27.94 (+1.42%)
PYPL   59.38 (+1.77%)
XOM   103.55 (-1.16%)
S&P 500   5,095.59 (+0.17%)
DOW   39,171.53 (+0.26%)
QQQ   437.93 (-0.03%)
AAPL   182.71 (-0.90%)
MSFT   409.79 (-0.45%)
META   487.22 (+0.22%)
GOOGL   143.98 (-0.08%)
AMZN   174.82 (+0.14%)
TSLA   193.83 (-1.81%)
NVDA   798.15 (+1.63%)
NIO   5.46 (-6.67%)
AMD   175.54 (-3.48%)
BABA   76.30 (+0.24%)
T   16.80 (+1.27%)
F   12.20 (+0.66%)
MU   85.83 (-0.09%)
CGC   3.26 (-3.26%)
GE   153.48 (+1.19%)
DIS   107.11 (-0.49%)
AMC   4.47 (+1.13%)
PFE   27.94 (+1.42%)
PYPL   59.38 (+1.77%)
XOM   103.55 (-1.16%)
S&P 500   5,095.59 (+0.17%)
DOW   39,171.53 (+0.26%)
QQQ   437.93 (-0.03%)
AAPL   182.71 (-0.90%)
MSFT   409.79 (-0.45%)
META   487.22 (+0.22%)
GOOGL   143.98 (-0.08%)
AMZN   174.82 (+0.14%)
TSLA   193.83 (-1.81%)
NVDA   798.15 (+1.63%)
NIO   5.46 (-6.67%)
AMD   175.54 (-3.48%)
BABA   76.30 (+0.24%)
T   16.80 (+1.27%)
F   12.20 (+0.66%)
MU   85.83 (-0.09%)
CGC   3.26 (-3.26%)
GE   153.48 (+1.19%)
DIS   107.11 (-0.49%)
AMC   4.47 (+1.13%)
PFE   27.94 (+1.42%)
PYPL   59.38 (+1.77%)
XOM   103.55 (-1.16%)
S&P 500   5,095.59 (+0.17%)
DOW   39,171.53 (+0.26%)
QQQ   437.93 (-0.03%)
AAPL   182.71 (-0.90%)
MSFT   409.79 (-0.45%)
META   487.22 (+0.22%)
GOOGL   143.98 (-0.08%)
AMZN   174.82 (+0.14%)
TSLA   193.83 (-1.81%)
NVDA   798.15 (+1.63%)
NIO   5.46 (-6.67%)
AMD   175.54 (-3.48%)
BABA   76.30 (+0.24%)
T   16.80 (+1.27%)
F   12.20 (+0.66%)
MU   85.83 (-0.09%)
CGC   3.26 (-3.26%)
GE   153.48 (+1.19%)
DIS   107.11 (-0.49%)
AMC   4.47 (+1.13%)
PFE   27.94 (+1.42%)
PYPL   59.38 (+1.77%)
XOM   103.55 (-1.16%)
NYSEAMERICAN:STXS

Stereotaxis (STXS) Stock Price, News & Analysis

$3.01
+0.20 (+7.12%)
(As of 12:44 PM ET)
Today's Range
$2.83
$3.08
50-Day Range
N/A
52-Week Range
$1.33
$3.29
Volume
152,428 shs
Average Volume
273,399 shs
Market Capitalization
$243.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.88

Stereotaxis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
60.4% Upside
$4.88 Price Target
Short Interest
Healthy
0.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.28mentions of Stereotaxis in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$19,023 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.28) to ($0.27) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.02 out of 5 stars


STXS stock logo

About Stereotaxis Stock (NYSEAMERICAN:STXS)

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

STXS Stock Price History

STXS Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Stereotaxis Inc STXS
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Stereotaxis Inc (RJR1.F)
Craig-Hallum Keeps Their Buy Rating on Stereotaxis (STXS)
Here's what Wall Street expects from Stereotaxis's earnings report
Recap: Stereotaxis Q3 Earnings
Stereotaxis Reports 2023 Third Quarter Financial Results
Stereotaxis Q3 2023 Earnings Preview
See More Headlines
Receive STXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
2/23/2024
Next Earnings (Estimated)
3/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:STXS
CIK
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.88
High Stock Price Target
$5.50
Low Stock Price Target
$4.00
Potential Upside/Downside
+62.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-18,290,000.00
Pretax Margin
-67.20%

Debt

Sales & Book Value

Annual Sales
$28.15 million
Book Value
$0.35 per share

Miscellaneous

Free Float
65,387,000
Market Cap
$243.48 million
Optionable
Not Optionable
Beta
1.31
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report














STXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Stereotaxis stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stereotaxis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STXS shares.
View STXS analyst ratings
or view top-rated stocks.

What is Stereotaxis' stock price target for 2024?

4 equities research analysts have issued 1 year target prices for Stereotaxis' shares. Their STXS share price targets range from $4.00 to $5.50. On average, they expect the company's stock price to reach $4.88 in the next twelve months. This suggests a possible upside of 60.4% from the stock's current price.
View analysts price targets for STXS
or view top-rated stocks among Wall Street analysts.

When is Stereotaxis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 1st 2024.
View our STXS earnings forecast
.

How were Stereotaxis' earnings last quarter?

Stereotaxis, Inc. (NYSEAMERICAN:STXS) issued its earnings results on Thursday, November, 11th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.03. The firm earned $9.11 million during the quarter, compared to the consensus estimate of $9 million. Stereotaxis had a negative net margin of 67.19% and a negative trailing twelve-month return on equity of 87.98%.

Who are Stereotaxis' major shareholders?

Stereotaxis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.00%), Essex Investment Management Co. LLC (1.45%), Kovack Advisors Inc. (0.28%), Independent Advisor Alliance (0.21%), Investors Research Corp (0.04%) and Cherry Creek Investment Advisors Inc. (0.04%).
View institutional ownership trends
.

How do I buy shares of Stereotaxis?

Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:STXS) was last updated on 2/23/2024 by MarketBeat.com Staff